CAMBRIDGE, Mass. & BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s CliniMACS CD34 Reagent ...
Miltenyi Biotec announced today that the FDA had approved its device for humanitarian use in patients with acute myeloid leukemia (AML) who are getting allogeneic stem cell transplants from matched, ...
T-cell depletion is an essential step in reducing the risk of graft-versus-host disease (GVHD) in patients with inherited metabolic storage diseases (IMSD) undergoing hematopoietic stem cell ...
Previous analyses of multicenter data reported to the Center for International Blood and Marrow Transplant Research to evaluate prognosis for recipients of myeloablative allo-HSCT, who survive without ...
Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft- ...
CliniMACS(R) CD34 Reagent System approved as a Humanitarian Use Device authorized by U.S. Federal law Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results